Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 391 to 405 of 2172 results for technology appraisal

  1. Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

    Awaiting development Reference number: GID-TA10605 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]

    Awaiting development Reference number: GID-TA10657 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease in people 12 to 17 years [TSID11887]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)

    Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin for people with mild chronic hepatitis C.

    Technology appraisal guidance
    Last updated
    27 November 2013
    View recommendations

    Sections for TA106

  6. Budesonide–glycopyrronium–formoterol fumarate for treating severe asthma in people 12 years and over TS ID 12018

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Aflibercept for untreated retinopathy in babies born preterm TS ID 11943

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)

    Evidence-based recommendations on lenvatinib (Lenvima) for untreated advanced hepatocellular carcinoma in adults.

    Technology appraisal guidance
    Published
    19 December 2018
    View recommendations

    Sections for TA551

  9. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (TA704)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies.

    Technology appraisal guidance
    Published
    26 May 2021
    View recommendations

    Sections for TA704

  10. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA870)

    Evidence-based recommendations on ixazomib with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.

    Technology appraisal guidance
    Published
    22 February 2023
    View recommendations

    Sections for TA870

  11. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development Reference number: GID-TA11221 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tofacitinib for moderate to severe rheumatoid arthritis (TA480)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating moderate to severe rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    11 October 2017
    View recommendations

    Sections for TA480

  13. Stapled haemorrhoidopexy for the treatment of haemorrhoids (TA128)

    Evidence-based recommendations on stapled haemorrhoidopexy for treating haemorrhoids in adults.

    Technology appraisal guidance
    Published
    26 September 2007
    View recommendations

    Sections for TA128

  14. Golimumab for treating moderately to severely active ulcerative colitis in people aged 2 to 17 years [TSID11959]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)

    Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    24 January 2018
    View recommendations

    Sections for TA499